Combining the HER2+ Breast Cancer Antibodies You Know in One Fixed-Dose Subcutaneous Injection ~ NEW

PROGRAM OBJECTIVES:

• Provide product overview including indication, important safety information, dosing, and administration

• Review clinical trial results including patient preference data Please note that this is a promotional educational program; CME credit will not be available.

INDICATIONS EARLY BREAST CANCER PHESGOTM (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC) • the adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) at high risk of recurrence Select patients for therapy based on an FDA-approved companion diagnostic test.

METASTATIC BREAST CANCER PHESGOTM is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic test.

REGISTER TODAY!